Actively Recruiting

Age: 18Years - 65Years
All Genders
NCT03893136

The Registry Study of Takayasu Arteritis in East China

Led by Shanghai Zhongshan Hospital · Updated on 2021-08-10

1000

Participants Needed

1

Research Sites

499 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The Takayasu arteritis (TA) is a rare inflammatory large vessel arteritis which often occurs women in Aisa, one of which is China. The rare cases restricted the development of intervention strategy, especially in female patients who plan to be pregnant. So investigators try to recruit as many TA participants as possible to build a TA cohort so that investigators could manage patients much more professionally and standardized and explore the better interventional strategy for a better outcome as well, with full use of blood and vascular tissues.

CONDITIONS

Official Title

The Registry Study of Takayasu Arteritis in East China

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Onset of symptoms at age 40 years or younger
  • Claudication (pain from too little blood flow) in an arm or leg
  • Decreased pulse in the brachial artery
  • Greater than 10 mm Hg difference in systolic blood pressure between arms
  • Presence of a bruit (sound) over the subclavian arteries or aorta
  • Imaging showing narrowing or blockage of the entire aorta or its main branches
  • Must meet at least 3 of the above 6 criteria
  • Signed informed consent
Not Eligible

You will not qualify if you...

  • Having autoimmune diseases such as ANCA-associated vasculitis, systemic lupus erythematosus, Behcet's disease, rheumatoid arthritis, or ankylosing spondylitis
  • Serious unrelated medical conditions affecting kidney, liver, blood, gastrointestinal, lung, heart, nervous system, or other organs
  • Malignant tumors
  • Serious acute or chronic infections
  • High risk or history of tuberculosis infection
  • Received or planning plasma exchange, lymphocyte replacement, or immunoabsorption therapy within 1 year
  • Planning to receive an attenuated vaccine during the trial
  • Received or planning to receive an organ transplant
  • Withdrawal during study due to adverse events or non-compliance with study protocol

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Department of Rheumatology in Zhongshan hospital, Fudan University

Shanghai, Shanghai Municipality, China, 200032

Actively Recruiting

Loading map...

Research Team

L

Lindi Jiang, PhD

CONTACT

R

Rongyi Chen, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here